Gene therapy for arthritis 1996 - 1999

Bibliography

• SELDIN MF, AMOS CI, WARD R, GREGERSEN PK: The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum. (1999) 42:1071–1079.
   PubMed Web of Science ®Google Scholar
• RYAN L, BROOKS P: Disease-modifying antirheumatic drugs. Curr. Opin. Rheumatol. (1999) 11:161–166.
   PubMedGoogle Scholar
• GIANNINI EH, RUPERTO N, RAVELLI A, LOVELL DJ, FELSON DT, MARTINI A: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. (1997) 40:1202–1209.
   PubMed Web of Science ®Google Scholar
• •One of the first clinical trials validating TNF-a as a therapeutic target in RA.
   Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl. J. Med. (1997) 337:141–147.
   Google Scholar
• •One of the first clinical trials validating TNF-a as a therapeutic target in RA.
   Google Scholar
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al: Etanercept therapy in rheumatoid arthritis. A random-ized, controlled trial. Ann. Intern. Merl. (1999) 130:478–486.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. J. Med. (1999) 340:253–259.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 344:1125–1127.
   PubMed Web of Science ®Google Scholar
• •One of the first clinical trials validating TNF-a as a therapeutic target in RA.
   Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. (1993) 36:1681–1690.
   PubMed Web of Science ®Google Scholar
• •One of the first clinical trials validating TNF-a as a therapeutic target in RA.
   Google Scholar
• LEFKOWITH JB: Cyclooxygenase-2 specificity and its clinical implications. Am. J. Med. (1999) 106:43S–50S.
   Google Scholar
• EVANS CH, GHIVIZZANI SC, KANG R et al: Gene therapy for rheumatic diseases. Arthritis Rheum. (1999) 42:1–16.
   PubMed Web of Science ®Google Scholar
• ••In-depth review of gene therapy strategies for rheumaticdiseases.
   Google Scholar
• EVANS CH, REDISKE JJ, ABRAMSON SB, ROBBINS PD: Joint efforts: tackling arthritis using gene therapy. Mol. Med. Today (1999) 5:148–151.
   Google Scholar
• LE CH, NICOLSON AG, MORALES A, SEWELL KL: Suppres-sion of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor alpha receptor gene. Arthritis Rheum. (1997) 40:1662–1669.
   PubMed Web of Science ®Google Scholar
• GHIVIZZANI SC, LECHMAN ER, KANG R et al: Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc. Natl. Acad. Sci. USA (1998) 95:4613–4618.
   PubMed Web of Science ®Google Scholar
• •Study providing evidence that local gene transfer can have distal effects in experimental models of RA.
   Google Scholar
• CHERNAJOVSKY Y, ADAMS G, PODHAJCER OL, MUELLER GM, ROBBINS PD, FELDMANN M: Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor. Gene Ther. (1995) 2:731–735.
   PubMed Web of Science ®Google Scholar
• MAGEED RA, ADAMS G, WOODROW D, PODHAJCER OL, CHERNAJOVSKY Y: Prevention of collagen-induced arthritis by gene delivery of soluble p75 tumour necrosis factor receptor. Gene Ther. (1998) 5:1584–1592.
   PubMed Web of Science ®Google Scholar
• EVANS CH, ROBBINS PD, GHIVIZZANI SC et al.: Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum. Gene Ther. (1996) 7:1261–1280.
   PubMed Web of Science ®Google Scholar
• ••Clinical protocol for the first gene therapy trial in patientswith RA.
   Google Scholar
• GHIVIZZANI SC, KANG R, MUZZONIGRO T et al: Gene therapy for arthritis - treatment of the first three patients [abstract]. Arthritis Rheum. (1997) 40:S223.
   Google Scholar
• FIRESTEIN GS, ECHEVERRI F, YEO M, ZVAIFLER NJ, GREEN DR: Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc. Nati Acad. Sci. USA (1997) 94:10895–10900.
   PubMed Web of Science ®Google Scholar
• ZHANG H, YANG Y, HORTON JL et al.: Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J. Clin. Invest. (1997) 100:1951–1957.
   PubMedGoogle Scholar
• OKAMOTO K, ASAHARA H, KOBAYASHI T et al.: Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Ther. (1998) 5:331–338.
   PubMed Web of Science ®Google Scholar
• BANDARA G, MUELLER GM, GALEA-LAURI J etal.: Intraar-ticular expression of biologically active interleukin 1-receptor- antagonist protein by ex vivo gene transfer. Proc. Natl. Acad. Sci. USA (1993) 90:10764–10768.
   Google Scholar
• ALTMAN RD, MOSKOWITZ R: Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J. Rheumatol. (1998) 25:2203–2212.
   PubMed Web of Science ®Google Scholar
• ROBAK T, GLADALSKA A, STEPIEN H, ROBAK E: Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. (1998) 7:347–353.
   PubMed Web of Science ®Google Scholar
• TAKAGI N, MIHARA M, MORIYA Y et al.: Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. (1998) 41:2117–2121.
   PubMed Web of Science ®Google Scholar
• KOCH AE: Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum. (1998) 41:951–962.
   PubMed Web of Science ®Google Scholar
• WANG Y, XU J, PIERSON T, O'MALLEY BW, TSAI SY: Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator. Gene Ther. (1997) 4:432–441.
   Google Scholar
• GOSSEN M, BUJARD H: Tight control of gene expression in mammalian cells by tetracycline- responsive promoters. Proc. Nati Acad. Sci. USA (1992) 89:5547–5551.
   PubMed Web of Science ®Google Scholar
• EVANS CH, HAND M, ROBBINS PD: Patenting gene therapy for arthritis. Exp. Opin. Ther. Patents (1996) 6:253–257.
   Web of Science ®Google Scholar